United States Biotechnology & Medical Research

Black Diamond Therapeutics Inc (BDTX)

Track

The most recent insider trading activity for Black Diamond Therapeutics Inc. occurred on March 19, 2025, involving significant share sales by Biotech Growth N.V. These transactions totaled several million shares. As these activities took place more than three months ago, no further context regarding current stock performance or recent market trends is provided.
Ticker: BDTX Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Black Diamond Therapeutics Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Sale 19 Mar 2025
Value US$3,271,116.26 | Price 473.25 | Shares 41,726 (+38.7%)
Sale 19 Mar 2025
Value US$1,540,082.64 | Price 377.47 | Shares 74,034 (+9.8%)
Sale 19 Mar 2025
Value US$837,160.00 | Price 2.09 | Shares 400,000 (-9.5%)
Sale 19 Mar 2025
Value US$4,000,800.00 | Price 2.00 | Shares 2,000,000 (-32.2%)
Sale 19 Mar 2025
Value US$2,308,100.00 | Price 2.31 | Shares 1,000,000 (-13.9%)
Sale 19 Mar 2025
Value US$582,900.00 | Price 1.94 | Shares 300,000 (-4.0%)
Sale 19 Mar 2025
Value US$2,069,100.00 | Price 2.07 | Shares 1,000,000 (-11.7%)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2025-03-20 2025-03-19 S Sale
2.1
BIOTECH GROWTH N V
Large shareholder
41,726 +38.7%
473.25
US$3,271,116 		41,726 +38.7% 473.25 US$3,271,116
2025-03-20 2025-03-19 S Sale
2.1
BIOTECH GROWTH N V
Large shareholder
74,034 +9.8%
377.47
US$1,540,083 		74,034 +9.8% 377.47 US$1,540,083
2025-03-20 2025-03-19 S Sale
2.1
BIOTECH GROWTH N V
Large shareholder
86,100 +0.1%
156.41
US$4,135,493 		86,100 +0.1% 156.41 US$4,135,493
2025-03-20 2025-03-19 S Sale
2.1
BIOTECH GROWTH N V
Large shareholder
2,000,000 -32.2%
2.00
US$4,000,800 		2,000,000 -32.2% 2.00 US$4,000,800
2025-03-20 2025-03-19 S Sale
2.1
BIOTECH GROWTH N V
Large shareholder
1,000,000 -13.9%
2.31
US$2,308,100 		1,000,000 -13.9% 2.31 US$2,308,100
2025-03-20 2025-03-19 S Sale
2.1
BIOTECH GROWTH N V
Large shareholder
300,000 -4.0%
1.94
US$582,900 		300,000 -4.0% 1.94 US$582,900
2025-03-20 2025-03-19 S Sale
2.1
BIOTECH GROWTH N V
Large shareholder
1,000,000 -11.7%
2.07
US$2,069,100 		1,000,000 -11.7% 2.07 US$2,069,100
2024-08-30 2024-08-28 S Sale
3.5
Versant Venture Capital VI, L.P.
Large shareholder
221,600 -5.6%
6.32
US$1,400,556 		221,600 -5.6% 6.32 US$1,400,556
2024-07-31 2024-07-31 PrS Proposed sale
David Epstein

Former Employer
50,000
6.20
US$310,000 		50,000 6.20 US$310,000
2024-07-26 2024-07-26 PrS Proposed sale
David Epstein

Former Employee
50,000
6.20
US$310,000 		50,000 6.20 US$310,000
2024-07-16 2024-07-16 PrS Proposed sale
David Epstein

Former Employer
50,000
6.25
US$312,500 		50,000 6.25 US$312,500
2024-07-11 2024-07-11 PrS Proposed sale
David Epstein

Former Employer
69,024
5.00
US$345,120 		69,024 5.00 US$345,120
2024-07-09 2024-07-09 PrS Proposed sale
David Esptein

Former Employee
75,000
4.80
US$360,000 		75,000 4.80 US$360,000
2024-06-28 2024-06-28 PrS Proposed sale
David Epstein

Former Employer
50,000
5.00
US$250,000 		50,000 5.00 US$250,000
2024-06-27 2024-06-27 PrS Proposed sale
David Epstein

Former Board Member
40,353
4.70
US$189,659 		40,353 4.70 US$189,659
2024-06-26 2024-06-26 PrS Proposed sale
David Epstein

Former Board Member
9,647
4.70
US$45,341 		9,647 4.70 US$45,341
2024-06-24 2024-06-24 PrS Proposed sale
David Epstein

Former Board Member
6,011
5.02
US$30,175 		6,011 5.02 US$30,175
2024-06-21 2024-06-21 PrS Proposed sale
David Epstein

Former Board Member
743
5.00
US$3,715 		743 5.00 US$3,715
2024-06-20 2024-06-20 PrS Proposed sale
David Epstein

Former board member
20,143
5.02
US$101,118 		20,143 5.02 US$101,118
2024-06-20 2024-06-20 PrS Proposed sale
Leah Wu

Spouse of former board member
20,268
5.02
US$101,745 		20,268 5.02 US$101,745
2024-06-18 2024-06-18 PrS Proposed sale
David Epstein

Former Board Member
2,951
5.45
US$16,083 		2,951 5.45 US$16,083
2024-06-14 2024-06-14 PrS Proposed sale
David Epstein

Former Board Member
24,621
6.03
US$148,465 		24,621 6.03 US$148,465
2024-06-13 2024-06-13 PrS Proposed sale
David Epstein

Former Board Member
70,853
6.15
US$435,746 		70,853 6.15 US$435,746
2024-06-12 2024-06-12 PrS Proposed sale
David Epstein

Former Board Member
62,528
6.14
US$383,922 		62,528 6.14 US$383,922
2023-10-19 2023-10-17 B Purchase
2.1
BIOTECH GROWTH N V
Large shareholder
400,000 +4.9%
2.34
US$934,080 		400,000 +4.9% 2.34 US$934,080
2023-07-07 2023-07-05 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director
935,850 +41.1%
5.00
US$4,679,250 		935,850 +41.1% 5.00 US$4,679,250
2023-07-06 2023-07-05 B Purchase
1.5
Behbahani Ali
Non-Executive Director
1,000,000 +29.0%
5.00
US$5,000,000 		1,000,000 +29.0% 5.00 US$5,000,000
2023-07-03 2023-06-30 B Purchase
2.1
BIOTECH GROWTH N V
Large shareholder
1,000,000 +14.0%
5.00
US$5,000,000 		1,000,000 +14.0% 5.00 US$5,000,000
2023-06-29 2023-06-27 B Purchase
2.1
BIOTECH GROWTH N V
Large shareholder
1,740,000 +32.4%
5.49
US$9,555,036 		1,740,000 +32.4% 5.49 US$9,555,036
2023-06-28 2023-06-27 PlS Planned sale
Epstein David M.

SEE REMARKS

Executive Director
25,000 -3.6%
6.70
US$167,500 		25,000 -3.6% 6.70 US$167,500
2023-06-27 2023-06-27 PrS Proposed sale
Epstein David M.

Officer

Officer
25,000
6.70
US$167,500 		25,000 6.70 US$167,500
2022-12-23 2022-12-22 B Purchase
3.6
Ni Fang

SEE REMARKS

Officer
36,363 +40.8%
1.28
US$46,596 		36,363 +40.8% 1.28 US$46,596
2022-12-23 2022-12-21 B Purchase
3.6
Ni Fang

SEE REMARKS

Officer
20,000 +29.0%
1.29
US$25,770 		20,000 +29.0% 1.29 US$25,770
2022-11-02 2022-10-31 B Purchase
2.1
BIOTECH GROWTH N V
Large shareholder
99,801 +1.9%
2.25
US$224,912 		99,801 +1.9% 2.25 US$224,912
2022-10-31 2022-10-28 B Purchase
2.1
BIOTECH GROWTH N V
Large shareholder
172,974 +3.4%
2.18
US$376,962 		172,974 +3.4% 2.18 US$376,962
2022-10-31 2022-10-27 B Purchase
2.1
BIOTECH GROWTH N V
Large shareholder
191,678 +3.9%
1.87
US$359,224 		191,678 +3.9% 1.87 US$359,224
2022-10-25 2022-10-21 B Purchase
2.1
BIOTECH GROWTH N V
Large shareholder
87,850 +1.8%
1.51
US$132,750 		87,850 +1.8% 1.51 US$132,750
2022-10-21 2022-10-20 B Purchase
2.1
BIOTECH GROWTH N V
Large shareholder
53,734 +1.1%
1.42
US$76,345 		53,734 +1.1% 1.42 US$76,345
2022-10-21 2022-10-19 B Purchase
2.1
BIOTECH GROWTH N V
Large shareholder
77,689 +1.7%
1.32
US$102,775 		77,689 +1.7% 1.32 US$102,775
2022-04-29 2022-04-28 B Purchase
2.1
BIOTECH GROWTH N V
Large shareholder
255,711 +5.8%
2.57
US$657,868 		255,711 +5.8% 2.57 US$657,868
2022-04-29 2022-04-27 B Purchase
2.1
BIOTECH GROWTH N V
Large shareholder
150,000 +3.5%
2.66
US$399,480 		150,000 +3.5% 2.66 US$399,480
2022-04-20 2022-04-19 B Purchase
2.1
BIOTECH GROWTH N V
Large shareholder
150,000 +3.6%
3.24
US$486,645 		150,000 +3.6% 3.24 US$486,645
2022-04-20 2022-04-18 B Purchase
2.1
BIOTECH GROWTH N V
Large shareholder
150,000 +3.8%
3.29
US$493,935 		150,000 +3.8% 3.29 US$493,935
2022-04-14 2022-04-13 B Purchase
2.1
BIOTECH GROWTH N V
Large shareholder
102,556 +2.6%
3.57
US$366,217 		102,556 +2.6% 3.57 US$366,217
2022-04-14 2022-04-12 B Purchase
2.1
BIOTECH GROWTH N V
Large shareholder
150,000 +4.0%
3.42
US$513,600 		150,000 +4.0% 3.42 US$513,600
2021-05-05 2021-05-03 PlS Planned sale
Roberts Christopher D.

Chief Scientific Officer

Officer
2,500 -43.9%
26.64
US$66,602 		2,500 -43.9% 26.64 US$66,602
2021-04-13 2021-04-12 PlS Planned sale
Hatzis-Schoch Brent

See Remarks

Officer
4,078 -32.7%
25.00
US$101,950 		4,078 -32.7% 25.00 US$101,950
2021-04-07 2021-04-05 PlS Planned sale
Roberts Christopher D.

Chief Scientific Officer

Officer
2,500 -43.9%
25.54
US$63,848 		2,500 -43.9% 25.54 US$63,848
2021-03-16 2021-03-12 PlS Planned sale
Hatzis-Schoch Brent

See Remarks

Officer
4,078 -32.7%
26.36
US$107,493 		4,078 -32.7% 26.36 US$107,493
2021-03-04 2021-03-03 PlS Planned sale
Roberts Christopher D.

Chief Scientific Officer

Officer
884 -21.6%
26.57
US$23,484 		884 -21.6% 26.57 US$23,484
2021-03-04 2021-03-03 PlS Planned sale
Roberts Christopher D.

Chief Scientific Officer

Officer
1,616 -28.4%
25.85
US$41,778 		1,616 -28.4% 25.85 US$41,778
2021-02-12 2021-02-12 PlS Planned sale
Hatzis-Schoch Brent

See Remarks

Officer
307 -3.5%
27.66
US$8,492 		307 -3.5% 27.66 US$8,492
2021-02-12 2021-02-12 PlS Planned sale
Hatzis-Schoch Brent

See Remarks

Officer
3,771 -30.2%
27.19
US$102,533 		3,771 -30.2% 27.19 US$102,533
2021-02-04 2021-02-03 PlS Planned sale
Roberts Christopher D.

Chief Scientific Officer

Officer
2,500 -43.9%
25.35
US$63,375 		2,500 -43.9% 25.35 US$63,375
2021-01-14 2021-01-12 PlS Planned sale
Hatzis-Schoch Brent

See Remarks

Officer
7,511 -47.2%
36.00
US$270,395 		7,511 -47.2% 36.00 US$270,395
2021-01-14 2021-01-12 PlS Planned sale
Hatzis-Schoch Brent

See Remarks

Officer
100 -0.6%
34.13
US$3,412 		100 -0.6% 34.13 US$3,412
2021-01-14 2021-01-12 PlS Planned sale
Hatzis-Schoch Brent

See Remarks

Officer
103 -0.6%
32.50
US$3,347 		103 -0.6% 32.50 US$3,347
2021-01-14 2021-01-12 PlS Planned sale
Hatzis-Schoch Brent

See Remarks

Officer
147 -0.9%
31.91
US$4,690 		147 -0.9% 31.91 US$4,690
2021-01-14 2021-01-12 PlS Planned sale
Hatzis-Schoch Brent

See Remarks

Officer
1,669 -9.3%
30.50
US$50,912 		1,669 -9.3% 30.50 US$50,912
2021-01-14 2021-01-12 PlS Planned sale
Hatzis-Schoch Brent

See Remarks

Officer
2,048 -10.3%
29.92
US$61,284 		2,048 -10.3% 29.92 US$61,284
2021-01-11 2021-01-08 PlS Planned sale
2.4
Leggett Thomas

Chief Financial Officer

Officer
3,000 -100.0%
33.94
US$101,820 		3,000 -100.0% 33.94 US$101,820
2021-01-06 2021-01-04 PlS Planned sale
Roberts Christopher D.

Chief Scientific Officer

Officer
537 -14.4%
31.78
US$17,065 		537 -14.4% 31.78 US$17,065
2021-01-06 2021-01-04 PlS Planned sale
Roberts Christopher D.

Chief Scientific Officer

Officer
1,963 -34.4%
31.31
US$61,460 		1,963 -34.4% 31.31 US$61,460
2021-01-06 2021-01-04 PlS Planned sale
Epstein David M.

See Remarks

Executive Director
2,015 -0.3%
31.80
US$64,075 		2,015 -0.3% 31.80 US$64,075
2021-01-06 2021-01-04 PlS Planned sale
Epstein David M.

See Remarks

Executive Director
9,985 -1.4%
30.99
US$309,430 		9,985 -1.4% 30.99 US$309,430
2020-12-16 2020-12-14 PlS Planned sale
Hatzis-Schoch Brent

See Remarks

Officer
4,078 -57.6%
34.95
US$142,522 		4,078 -57.6% 34.95 US$142,522
2020-12-10 2020-12-08 PlS Planned sale
2.4
Leggett Thomas

Chief Financial Officer

Officer
1,941 -100.0%
34.05
US$66,094 		1,941 -100.0% 34.05 US$66,094
2020-12-10 2020-12-08 PlS Planned sale
2.4
Leggett Thomas

Chief Financial Officer

Officer
1,059 -35.3%
33.27
US$35,233 		1,059 -35.3% 33.27 US$35,233
2020-12-04 2020-12-03 PlS Planned sale
Roberts Christopher D.

Chief Scientific Officer

Officer
2,500 -100.0%
32.42
US$81,055 		2,500 -100.0% 32.42 US$81,055
2020-12-03 2020-12-01 PlS Planned sale
Epstein David M.

See Remarks

Executive Director
1,077 -0.2%
33.45
US$36,021 		1,077 -0.2% 33.45 US$36,021
2020-12-03 2020-12-01 PlS Planned sale
Epstein David M.

See Remarks

Executive Director
10,923 -1.5%
32.64
US$356,553 		10,923 -1.5% 32.64 US$356,553
2020-12-01 2020-11-30 PlS Planned sale
3.3
Bolzon Bradley J PhD
Non-Executive Director Large shareholder
200 -0.0%
34.16
US$6,833 		200 -0.0% 34.16 US$6,833
2020-12-01 2020-11-30 PlS Planned sale
3.3
Bolzon Bradley J PhD
Non-Executive Director Large shareholder
10,193 -1.2%
33.13
US$337,680 		10,193 -1.2% 33.13 US$337,680
2020-12-01 2020-11-30 PlS Planned sale
3.5
Versant Venture Capital VI, L.P.
Large shareholder
200 -0.0%
34.16
US$6,833 		200 -0.0% 34.16 US$6,833
2020-12-01 2020-11-30 PlS Planned sale
3.5
Versant Venture Capital VI, L.P.
Large shareholder
10,193 -1.2%
33.13
US$337,680 		10,193 -1.2% 33.13 US$337,680
Explore more

More insider trading research around Black Diamond Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America